Antineo : Myeloma tumour model – MM1S
-
MM1S cells
Human MM1S cells were isolated from the peripheral blood of a patient with a IgA lambda myeloma.
-
Tumour growth in vivo
The cells were collected from a tissue culture flask and injected subcutaneously in the right flank of SCID-CB17 mice. The resulting tumours were monitored by measuring two diameters with calipers, and extrapolating the volume to a sphere.
The mice bearing MM1S tumours can be treated by intra-peritoneal, intra-venous, intra-tumoral or subcutaneous injection of the compounds. Per os administration is also possible.
Figure 1: (View PDF)
Tumour growth curve of the MM1S cells as xenograft Mean ± SEM (n=4; take rate 100%)
-
Standard-Of-Care Drug Reponses
daratumumab 15 mg/kg qw → Response
Figure 2: (View PDF)
Effect of daratumumab treatment on RPMI 8226 tumour growth Mean ± SEM (n=4 per group; take rate 100%)
A MM1S model fully resistant to daratumumab, developed in vivo without genetic modifications, are available at Antineo.